Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...
An Eli Lilly exec said the company’s experimental weight-loss pill could make GLP-1 treatments more accessible worldwide, as ...
Like many pharma stocks, Eli Lilly (NYSE: LLY) offers investors a bit of safety -- and it's an element you can count on ...
A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are ...
Eli Lilly is set to launch its popular weight-loss drug in emerging markets, including India, Brazil, and Mexico, by mid-2025 ...
Eli Lilly plans to globally launch its diabetes and weight-loss drug, Mounjaro, in countries including China, India, Brazil, ...
Semaglutide and tirzepatide confer greater improvements in life expectancy than naltrexone/bupropion and ...
Pharmaceutical Technology on MSN2d
Viking strikes $150m deal to secure supply of obesity drugViking Therapeutics has inked a $150m multi-year manufacturing deal with CordenPharma to secure the future supply of its ...
Cristina Arias / Cover / Getty Images Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss pharmaceutical firm signed an exclusive ...
Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...
Roche (RHHBY) is increasing its investment into the obesity space with an up to $5.3 billion deal with Danish drugmaker ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback